Pub. Date : 2014
PMID : 24647522
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | RESULTS: In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). | gemcitabine | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 2 | RESULTS: In patients receiving gemcitabine-based therapy, the disease control rate (DCR) and progression-free survival (PFS) of patients with RRM1-negative tumors were significantly higher than in patients with RRMI-positive tumors (P = 0.041 and P = 0.01, respectively), and multivariate analysis showed that RRM1 expression was an independent prognostic factor (P = 0.013). | gemcitabine | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 3 | In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). | gemcitabine | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 4 | In RRM1-positive patients, the DCRs for docetaxel and vinorelbine were higher than for gemcitabine (P = 0.047 and P = 0.047, respectively), and docetaxel and vinorelbine showed a longer PFS than gemcitabine-based chemotherapy (P = 0.012 and P = 0.007). | gemcitabine | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 5 | CONCLUSIONS: Negative RRM1 expression in advanced NSCLC is associated with a higher response rate to gemcitabine-based chemotherapy. | gemcitabine | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |